No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LLY240726C927500
- 0.57
- -0.43-43.00%
15min DelayClose Jul 22 16:00 ET
1.38High0.57Low
1.38Open1.00Pre Close26 Volume21 Open Interest927.50Strike Price1.96KTurnover36.41%IV7.17%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.57Extrinsic Value100Contract SizeAmericanOptions Type0.0447Delta0.0028Gamma1396.73Leverage Ratio-0.3300Theta0.0045Rho62.43Eff Leverage0.0888Vega
Intraday
- 5D
- Daily
News
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright analyst initiated coverage on AnaptysBio Inc (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering immunology therapeutics.AnaptysBio has a pipeline of checkpoint
The S&P 500 Typically Outperforms in July, Underperforms August-October - RBC Capital Markets
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
The race to develop oral weight loss medications is intensifying as companies like Roche Holdings AG (OTC:RHHBY), Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE)
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
By Adam Clark Eli Lilly and Novo Nordisk are sitting pretty in the pharmaceutical sector due to their weight-loss drugs. While the market has been nervous about potential competition, investors can
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Up to 20% weight loss! Eli Lilly and Co's Theralogix (Tesofensine) approved in China, stronger effect than Sibutramine?
Is the competition intensifying?
Comments
From YouTube
7
7
HahaJim Cramer remains optimistic about the long-term prospects of megacap stocks, even as they continue to decline.
“I think if you’re willing to own them for the long-haul and take some pain, you’ll continue to win,” Cramer said. He encourages investors to take profits on winners when possible to avoid getting "obliterated," but acknowledges that owning losers can feel more difficult.
Cramer reviewed the bear cases for the Mag...
“I think if you’re willing to own them for the long-haul and take some pain, you’ll continue to win,” Cramer said. He encourages investors to take profits on winners when possible to avoid getting "obliterated," but acknowledges that owning losers can feel more difficult.
Cramer reviewed the bear cases for the Mag...
5
2
In the afternoon, the U.S. stock market experienced a significant sell-off, with both $Nasdaq Composite Index(.IXIC.US$ and $S&P 500 Index(.SPX.US$dropping over 1% intraday. $Dow Jones Industrial Average(.DJI.US$ ended up falling more than 530 points, closing down 1.3%, snapping a six-day winning streak and falling short of a new high.
The Russell 2000 index of small-cap stocks $Russell 2000 Index(.RUT.US$dropped nearly 2%, continuing its decline for the second consecutive day after bei...
The Russell 2000 index of small-cap stocks $Russell 2000 Index(.RUT.US$dropped nearly 2%, continuing its decline for the second consecutive day after bei...
3
Read more